Companies › HTA
3 active drug programs in 6 registered trials: 3 Phase 3, 3 Phase 2; Other, Neurology, Metabolic and endocrine, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | NETS Ga68 Lu177 | Nov 2026 |
| [18F]Fluorbetazine injection PET tracer for amyloid-beta plaque imaging | APP | Phase 3 | Mild Cognitive Impairment (MCI) | Dec 2027 |
| 68Ga-DOTATATE Injection Somatostatin receptor 2 (SSTR2) agonist/imaging agent | SSTR2 | Phase 3 | NETs; Healthy (Controls); Metastic Thyroid Cancer; ACTH | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07119242 | 68Ga-DOTATATE Injection | Phase 3 | NETs | Other | Nov 2024 |
| NCT07057622 | Lutetium Oxodotreotide Lu-177 | Phase 3 | NETS Ga68 Lu177 | Other | Nov 2026 |
| NCT07764679 | [18F]Fluorbetazine injection | Phase 3 | Mild Cognitive Impairment (MCI) | Neurology | Dec 2027 |
| NCT07284589 | 68Ga-DOTATATE Injection | Phase 2 | Healthy (Controls) | Oncology | Apr 2030 |
| NCT04927416 | 68Ga-DOTATATE Injection | Phase 2 | Metastic Thyroid Cancer | Oncology | Nov 2030 |
| NCT02019706 | 68Ga-DOTATATE Injection | Phase 2 | ACTH | Metabolic and endocrine | Dec 2030 |
AgelessRx Biotechnology Institute IMASD Epygenix Huons Biopharma Neuren Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.